15.6 C
London
Thursday, September 29, 2022
HomeBusinessOncology Based In-vivo CRO Market Trends 2022-27, Size, Share, Growth, Report, Analysis,...

Oncology Based In-vivo CRO Market Trends 2022-27, Size, Share, Growth, Report, Analysis, Top Companies and Forecast

Date:

Related stories

Best Astrologers You Need To Know About

When anything goes wrong, we know to attribute it...

Luxury Carpet and Living room curtains in Dubai

Luxury carpets and Curtains in Dubai are one of...

Video Call for KYC Verification – Advanced Method to Onboard Genuine Clients

For businesses, using internet platforms proved more challenging than...

What’s iFun tv and For what purpose Do you need to make use of iFuntv?

These days, you could slightly hold things below manipulate...
spot_imgspot_img

According to the latest report by IMARC Group, titled “Global Oncology Based In-vivo CRO Market Trends, Size, Share, Growth, Opportunity and Forecast 2022-2027“, it is expected to reached a value of US$ 1.05 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 1.69 Billion by 2027, exhibiting a CAGR of 7.81% during 2022-2027.

Oncology is a branch of medicine that studies, diagnoses, and treats cancer using various methods such as biopsy, endoscopy, X-ray, computed tomography (CT) scanning, magnetic resonance imaging (MRI), and positron emission tomography (PET) scanning. On the other hand, oncology based in-vivo CRO refers to the method of treating cancer using contract research organization services. These services conduct research with living organisms such as animals, plants, or whole cells for pharmaceutical, biotechnology, and medical device industries on a contractual basis. In recent years, there has been an escalating demand for oncology based in-vivo CRO due to the development of several investigational compounds for treating cancer.

Oncology Based In-Vivo CRO Market Report Scope
Report CoverageDetails
Market size value in 2021US$ 1.05 Billion
Market forecast in 2027US$ 1.69 Billion
Growth RateCAGR of 7.81% from 2022 to 2027
Base year for estimation2021
Historical data2016-2021
Forecast period2022-2027

Oncology Based In-Vivo CRO Market Trends and Drivers:

The market is primarily driven by the growing prevalence of cancer across the globe. In addition, the introduction of advanced genetic engineering that helps manipulate deoxyribonucleic acid (DNA) and alter the characteristics of various organisms represents another major growth-inducing factor.

Request a Free PDF Sample for more detailed market insights: https://www.imarcgroup.com/oncology-based-in-vivo-cro-market/requestsample

Besides this, contract research organizations (CROs) are conducting extensive research and development (R&D) activities to gain expertise in cancer treatment. They are also offering cost-effective services that are more economical than in-house study. This, coupled with the rising adoption of telehealth and virtual clinical trials in the healthcare industry to ensure the safety of cancer patients, is creating a positive market outlook across the globe.

Moreover, the expanding healthcare industry and the increasing investments by the governments of numerous countries to conduct clinical trials and research activities are also contributing to the market growth.

Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Global Oncology Based In-Vivo CRO Market 2022-2027 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these top key players include: 

Champions Oncology Inc., Charles River Laboratories International Inc., Crown Bioscience Inc., Eurofins Scientific, Evotec SE, ICON Plc, Labcorp Drug Development (Laboratory Corporation of America Holdings), Living Tumor Laboratory, Taconic Biosciences Inc., The Jackson Laboratory, WuXi AppTec and Xentech.

The report has segmented the market on the basis of region, indication, model and application.

Breakup by Indication:

  • Blood Cancer
  • Solid Tumors
  • Others

Breakup by Model:

  • Syngeneic
  • Xenograft
  • Patient Derived Xenograft (PDX)
  • Others

Breakup by Application:

  • Hospitals
  • Rehabilitation Centers

Breakup by Region:

  • North America: (United States, Canada)
  • Asia Pacific: (China, Japan,India, South Korea, Australia, Indonesia, Others)
  • Europe: (Germany, France,United Kingdom, Italy, Spain, Russia, Others)
  • Latin America: (Brazil, Mexico, Others)
  • Middle East and Africa

Inquire Before Buying : https://www.imarcgroup.com/request?type=report&id=5438&flag=F

If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.

Key highlights of the report:

  • Market Performance (2016-2021)
  • Market Outlook (2022- 2027)
  • Porter’s Five Forces Analysis
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Value Chain
  • Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories

spot_img

LEAVE A REPLY

Please enter your comment!
Please enter your name here